Somatic symptom disorder linked to changes in brain functional connectivity
April 3, 2019 – Alterations in functional connectivity of the brain may help in understanding the neurobiological changes leading to somatic symptom disorder (SSD), reports a study in Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society. The journal is published in the Lippincott Portfolio by Wolters Kluwer.
The new research by Doug Hyun Han, MD, PhD, and colleagues of Chung-Ang University, Republic of Korea, provides a deeper understanding of how connectivity within and between brain networks may differ in people with SSD, compared to healthy controls. The findings may help in understanding what’s going on in the brains of patients with disabling anxiety and distress related to physical symptoms.
New Insights into Functional Connections of the Brain in People with SSD
Patients with SSD have persistent worry about bodily symptoms that are misinterpreted as medical diseases. The study included 18 patients with SSD and 20 healthy controls: 13 women and five men, average age 47 years. Seven were classified as having the “predominant pain” subtype of SSD.
Using a technique called functional magnetic resonance imaging (fMRI), the researchers assessed functional connectivity – interactions and synchronized activity – between different areas of the brain in SSD patients versus controls. The fMRI data were analyzed to explore connections within and between four previously defined “brain networks” with specialized functions. Within three of the four brain networks studied, functional connectivity was greater in the patients with SSD, compared to the healthy controls.
The study also found increased functional connectivity between certain brain networks in patients with SSD. Scores on a widely used SSD questionnaire (the Somato-Sensory Amplification Scale) were correlated with the level of functional connectivity between some of the networks.
Specifically, SSD was related to functional connections between the sensorimotor network (SMN), involved in processing somatosensory information and planning motor tasks (movement); and the salience network, involved in detecting and integrating emotional and sensory stimuli. Based on this interaction, SSD may be related to changes in the sensory processing of pain and other symptoms, which is influenced by emotional (affective) processing. Patients with SSD may also have “magnified labeling of pain intensity” and increased attention to the “affective or unpleasant component of physical pain,” according to the authors.
Scores on the SSD questionnaire were also related to functional connectivity between the SMN and the dorsal attention network, which is involved in goal-directed and stimulus-driven attention. Based on this connection, Dr. Han and coauthors write, “[P]atients with SSD have a deficit in attention, leading to misperception of external stimuli and failure to regulate bodily functions aimed at interactions with external stimuli.”
Somatic symptom disorder is a common condition, affecting an estimated five to seven percent of the population. People with SSD have high rates of depression and anxiety and poor quality of life, with frequent medical visits and high healthcare costs. Despite progress in research on SSD, there are no established biomarkers of this condition.
Building on previous studies, the new findings show increased functional connections within and between certain brain networks in people living with SSD. These differences in brain functional connectivity may lend new insights into the underlying neurobiology of this condition. Dr. Han and colleagues highlight the need for further studies including larger numbers of people with SSD, including assessment of possible differences by sex and comparison with patients with physical disease who have similar levels and types of symptoms.
Click here to read “Brain Functional Connectivity in Patients With Somatic Symptom Disorder”
About Psychosomatic Medicine
Psychosomatic Medicine: Journal of Biobehavioral Medicine, founded in 1939, is the official peer-reviewed journal of the American Psychosomatic Society. It publishes experimental and clinical studies dealing with various aspects of the relationships among social, psychological, and behavioral factors and bodily processes in humans and animals. Psychosomatic Medicine: Journal of Biobehavioral Medicine is an international, interdisciplinary journal devoted to experimental and clinical investigation in behavioral biology, psychiatry, psychology, physiology, anthropology, and clinical medicine. The print journal is published nine times a year; most articles are published online ahead of print.
About the American Psychosomatic Society
The mission of the American Psychosomatic Society is to promote and advance the scientific understanding and multidisciplinary integration of biological, psychological, behavioral and social factors in human health and disease, and to foster the dissemination and application of this understanding in education and health care.
The American Psychosomatic Society is a worldwide community of scholars and clinicians dedicated to the scientific understanding of the interaction of mind, brain, body and social context in promoting health. The organization is devoted to biopsychosocial research and integrated clinical care, and to providing a forum via its website, Annual Meeting and journal, Psychosomatic Medicine, for sharing this research. Its members are from around the world, including specialists from all medical and health-related disciplines, the behavioral sciences, and the social sciences.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information, software solutions, and services for the health, tax & accounting, finance, risk & compliance, and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer, headquartered in the Netherlands, reported 2017 annual revenues of €4.4 billion. The company serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit http://healthclarity.